122 related articles for article (PubMed ID: 3182416)
21. The comparative in-vitro activity of pefloxacin.
King A; Phillips I
J Antimicrob Chemother; 1986 Apr; 17 Suppl B():1-10. PubMed ID: 2940213
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998.
Huczko E; Conetta B; Bonner D; Valera L; Stickle T; Macko A; Fung-Tomc J
Int J Antimicrob Agents; 2000 Dec; 16(4):401-5. PubMed ID: 11118848
[TBL] [Abstract][Full Text] [Related]
23. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
Shonekan D; Mildvan D; Handwerger S
Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of PD 117596-2, a broad-spectrum difluoroquinolone.
Neu HC; Chin NX
Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):644-50. PubMed ID: 2506029
[TBL] [Abstract][Full Text] [Related]
25. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.
Wise R; Andrews JM; Brenwald N
J Antimicrob Chemother; 1993 Apr; 31(4):497-504. PubMed ID: 8390433
[TBL] [Abstract][Full Text] [Related]
26. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
Harnett SJ; Fraise AP; Andrews JM; Jevons G; Brenwald NP; Wise R
J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
Dalhoff A; Petersen U; Endermann R
Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
[TBL] [Abstract][Full Text] [Related]
28. Antibacterial activity of lomefloxacin.
Leigh DA; Tait S; Walsh B
J Antimicrob Chemother; 1991 May; 27(5):589-98. PubMed ID: 1885417
[TBL] [Abstract][Full Text] [Related]
29. In vitro studies of fleroxacin (Ro 23-6240), a new trifluorinated quinolone derivative.
Digranes A; Benonisen E; Salveson A; Zahm F
Chemotherapy; 1988; 34(5):401-10. PubMed ID: 3141116
[TBL] [Abstract][Full Text] [Related]
30. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients.
Rolston K; Ho DH; LeBlanc B; Bodey GP
Chemotherapy; 1988; 34(6):448-54. PubMed ID: 3149568
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime.
Jones RN; Barry AL; Thornsberry C
Antimicrob Agents Chemother; 1989 Jun; 33(6):944-50. PubMed ID: 2504106
[TBL] [Abstract][Full Text] [Related]
33. The in vitro activity of BMS-284756, a new des-fluorinated quinolone.
Weller TM; Andrews JM; Jevons G; Wise R
J Antimicrob Chemother; 2002 Jan; 49(1):177-84. PubMed ID: 11751785
[TBL] [Abstract][Full Text] [Related]
34. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
Ismaeel NA; Tayeb OS
Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
[TBL] [Abstract][Full Text] [Related]
35. The comparative in-vitro activity of ofloxacin.
Grüneberg RN; Felmingham D; O'Hare MD; Robbins MJ; Perry K; Wall RA; Ridgway GL
J Antimicrob Chemother; 1988 Sep; 22 Suppl C():9-19. PubMed ID: 3182468
[TBL] [Abstract][Full Text] [Related]
36. In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent.
Cohen MA; Huband MD; Mailloux GB; Yoder SL; Roland GE; Domagala JM; Heifetz CL
Antimicrob Agents Chemother; 1991 Jan; 35(1):141-6. PubMed ID: 2014970
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of E-4868, a new trifluoroquinolone, compared to six similar compounds.
Barrett MS; Jones RN; Erwin ME
Eur J Clin Microbiol Infect Dis; 1993 Feb; 12(2):134-41. PubMed ID: 8388792
[TBL] [Abstract][Full Text] [Related]
38. Comparative in vitro activity of cefpirome and cefepime, two new cephalosporins.
King A; Boothman C; Phillips I
Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):677-85. PubMed ID: 2226498
[TBL] [Abstract][Full Text] [Related]
39. Multicenter Spanish study of ciprofloxacin susceptibility in gram-negative bacteria. The Spanish Study Group on Quinolone Resistance.
García-Rodríguez JA; Fresnadillo MJ; García MI; García-Sánchez E; García-Sánchez JE; Trujillano I
Eur J Clin Microbiol Infect Dis; 1995 May; 14(5):456-9. PubMed ID: 7556239
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
